Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10751 - 10775 of 12591 in total
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Investigational
Matched Description: … investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of ... Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia …
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the ... products that have been withdrawn or removed from the market for reasons of safety or effectiveness. …
The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most...
Investigational
Matched Description: … in gastric tissues with the source for them being predominantly stromal cells, although expression of ... The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing ... The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected …
XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and...
Investigational
Matched Description: … response to a variety of DNA damaging agents. ... XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in ... Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and serine/threonine-protein …
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … activities against specific types of cancer. ... NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse ... NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer of
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of...
Investigational
Matched Description: … IGF-IR is overexpressed in a variety of tumour types. ... , Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. ... Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia …
J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated...
Experimental
Matched Description: … experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of ... derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of ... neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of
A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as 1,2-diacyl-3-phosphocholines. Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. The emulsifying and surfactant properties are useful in food additives and...
Experimental
Matched Description: … A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines ... Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. …
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593]. ... The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles ... Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge …
Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).
Investigational
Matched Description: … Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 ... on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 …
Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms).
Investigational
Matched Description: … Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 …
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of ... various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related …
DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve.
Investigational
Matched Description: … for the treatment of glaucoma. ... DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed …
IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.
Investigational
Matched Description: … It is being devloped by Intercell AG for the treatment of hepatitis C. ... The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell …
Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination With Ad-cea Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004).
Investigational
Matched Description: … Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). ... Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination …
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
Matched Description: … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble ... Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid …
Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).
Investigational
Matched Description: … Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib …
Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Investigational
Matched Description: … the body, including in the airways of humans and many other species. ... It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout …
MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Investigational
Matched Description: … patients with all stages of prostate, pancreatic and bladder cancers. ... Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
Matched Description: … It consists of an adeno-associated virus vector containing an expression cassette of the human Factor …
ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients. These cells are...
Investigational
Matched Description: … ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human ... Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured ... Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified …
In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis,...
Illicit
Investigational
Withdrawn
Matched Description: … However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development ... In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled ... of Monase was halted and the drug was withdrawn from potential market use. …
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and ... It is developed for the treatment of several serious women’s health conditions including endometrial …
Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed. It presents a unique chemical structure that does not follow the structural properties of other drugs of its class. Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. However, it...
Experimental
Matched Description: … of its class. ... It presents a unique chemical structure that does not follow the structural properties of other drugs ... However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic …
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … of the vaccine. ... LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV ... As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity …
Displaying drugs 10751 - 10775 of 12591 in total